|
94 Companies |
|
165 Products |
|
165 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
1453 News |
|
| «12...4567891011121314...2930» |
- | CAT-2003 / Astria Therap
Enrollment closed, Trial primary completion date: Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia (clinicaltrials.gov) - Feb 19, 2015
P2, N=18, Active, not recruiting, Sponsor: Catabasis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Apr 2015
- ||| obicetrapib (TA-8995) / NewAmsterdam Pharma
Trial completion: Study of the Electrocardiographic Effects of TA-8995 (clinicaltrials.gov) - Feb 19, 2015
P1, N=136, Completed, Sponsor: Xention Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Apr 2015 Recruiting --> Completed
- Enrollment open: Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy (clinicaltrials.gov) - Feb 18, 2015
P1, N=20, Recruiting, Sponsor: VA Northern California Health Care System
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| bococizumab (RN316) / Pfizer
Trial completion: Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects (clinicaltrials.gov) - Feb 10, 2015
P2, N=218, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Completed
- Praluent (alirocumab) / Sanofi, Regeneron
Trial primary completion date: Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol (clinicaltrials.gov) - Feb 9, 2015
P1, N=21, Recruiting, Sponsor: Sanofi
Recruiting --> Completed Trial primary completion date: Oct 2015 --> May 2015
- ||| Trial completion: Tailored Communication to Reduce Cardiovascular Risk (clinicaltrials.gov) - Feb 9, 2015
P=N/A, N=464, Completed, Sponsor: Northwestern University
Trial primary completion date: Oct 2015 --> May 2015 Active, not recruiting --> Completed
- || Trial primary completion date: Portfolio 5 - Multicentre Dietary Advice on Serum Lipids in Hyperlipidemia (clinicaltrials.gov) - Feb 6, 2015
P2, N=220, Active, not recruiting, Sponsor: University of Toronto
Active, not recruiting --> Completed Trial primary completion date: Jan 2014 --> Jan 2011
- Trial completion: Alternative Treatments for Menopausal Women (clinicaltrials.gov) - Feb 6, 2015
P=N/A, N=61, Completed, Sponsor: Aarhus University Hospital
Trial primary completion date: Jan 2014 --> Jan 2011 Recruiting --> Completed
- Olbetam (acipimox) / Pfizer
Trial completion, Trial primary completion date: Effects of Acipimox on Mitochondrial Function in Obesity (clinicaltrials.gov) - Feb 6, 2015
P2, N=39, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2015
- |||| Kynamro (mipomersen) / Kastle Therap
Trial primary completion date: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia (clinicaltrials.gov) - Feb 5, 2015
P3, N=142, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2015 Trial primary completion date: Mar 2014 --> Sep 2014
- | Trial completion, MRI: Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=21, Completed, Sponsor: Beth Israel Deaconess Medical Center
Trial primary completion date: Mar 2014 --> Sep 2014 Recruiting --> Completed
- | human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
Trial completion: Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (clinicaltrials.gov) - Feb 5, 2015
P2, N=23, Completed, Sponsor: Cerenis Therapeutics, SA
Recruiting --> Completed Active, not recruiting --> Completed
- | CAT-2003 / Astria Therap
Trial completion, Enrollment change: Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia (clinicaltrials.gov) - Feb 3, 2015
P2, N=16, Completed, Sponsor: Catabasis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=12 --> 16
- Trial completion: A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=40, Completed, Sponsor: CAMC Health System
Active, not recruiting --> Completed | N=12 --> 16 Recruiting --> Completed
- ||||| rosuvastatin / Generic mfg.
Enrollment change: An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia (clinicaltrials.gov) - Feb 2, 2015
P3, N=250, Completed, Sponsor: AstraZeneca
Recruiting --> Completed N=198 --> 250
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Trial primary completion date: Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1) (clinicaltrials.gov) - Feb 2, 2015
P3, N=803, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=198 --> 250 Trial primary completion date: Mar 2015 --> Sep 2014
- Clinical: Characterization of the Metabolic Fate of an Oral Arginine Form (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=32, Completed, Sponsor: Institut National de la Recherche Agronomique
- ||||||| Praluent (alirocumab) / Sanofi, Regeneron
Trial completion: ODYSSEY FH II: Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) (clinicaltrials.gov) - Feb 2, 2015
P3, N=249, Completed, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Mar 2015 --> Sep 2014 Active, not recruiting --> Completed
- ||| Trial completion, Enrollment change, Adherence: FIMA: Financial Incentives for Medication Adherence (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=74, Completed, Sponsor: Boston Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 74
- | rosuvastatin / Generic mfg.
Enrollment closed: HYDRA: A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Jan 30, 2015
P3, N=25, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed | N=100 --> 74 Recruiting --> Active, not recruiting
- ||||||| Praluent (alirocumab) / Sanofi, Regeneron
Trial completion: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH) (clinicaltrials.gov) - Jan 28, 2015
P3, N=107, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial primary completion date: Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: Chandan K Sen
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Dec 2015
- Clinical: 15001Analy: Clinical Trial of Transtek Body Fat Analyzer (GBF-835-N2 & Other 7 Models) (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=60, Completed, Sponsor: Leo Wang
- ||| Clinical: A Study to Identify and Characterize LAL-D Patients in High-risk Populations (clinicaltrials.gov) - Jan 26, 2015
P=N/A, N=10000, Recruiting, Sponsor: Synageva BioPharma Corp.
- ||||| Repatha (evolocumab) / Amgen, Astellas
Enrollment closed: GLAGOV: GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound (clinicaltrials.gov) - Jan 26, 2015
P3, N=970, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Apr 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- acetylcysteine solution / Generic mfg.
Phase classification, Combination therapy: Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis (clinicaltrials.gov) - Jan 22, 2015
P4, N=10, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Active, not recruiting Phase classification: P2 --> P4
- BioAstin (astaxanthin) / Cyanotech
Clinical: LLAX: Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=68, Recruiting, Sponsor: Ajinomoto Foods Europe SAS
- Enrollment open: A Trial to Evaluate the Efficacy of AB-Life Probiotic Product on LDL-Cholesterol Reduction in Moderate Hypercholesterolemia (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=104, Recruiting, Sponsor: AB Biotics, SA
Phase classification: P2 --> P4 Not yet recruiting --> Recruiting
- Enrollment change, Trial withdrawal, Trial primary completion date, MRI: MRIPD#7: Magnetic Resonance Imaging-Portfolio Diet Study #7 (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=0, Withdrawn, Sponsor: St. Michael's Hospital, Toronto
Not yet recruiting --> Recruiting N=194 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2018 --> Dec 2014
- Enrollment change, Trial withdrawal, Trial primary completion date: EDP8: Enhanced Multicenter Dietary Portfolio Study (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=0, Withdrawn, Sponsor: St. Michael's Hospital, Toronto
N=194 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2018 --> Dec 2014 N=200 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2015 --> Sep 2013
- | New P1 trial: Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy (clinicaltrials.gov) - Jan 20, 2015
P1, N=20, Not yet recruiting, Sponsor: VA Northern California Health Care System
- Trial completion, IO biomarker: Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=125, Completed, Sponsor: University Hospital Freiburg
N=200 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2015 --> Sep 2013 Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: LIPOGENE: Identification of a New Gene Involved in Hereditary Lipodystrophy (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=2, Completed, Sponsor: University Hospital, Bordeaux
Recruiting --> Completed Recruiting --> Completed | N=27 --> 2 | Trial primary completion date: Jun 2014 --> Jan 2014
- || trigonellinamide (TRIA-662) / Cortria
Trial primary completion date: A Pilot Study to Evaluate the Lipid Effects of TRIA-662 (clinicaltrials.gov) - Jan 13, 2015
P2, N=64, Recruiting, Sponsor: Cortria Corporation
Recruiting --> Completed | N=27 --> 2 | Trial primary completion date: Jun 2014 --> Jan 2014 Trial primary completion date: Sep 2014 --> Sep 2015
- ||||| Repatha (evolocumab) / Amgen, Astellas
Enrollment closed, Combination therapy: FLOREY: Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (clinicaltrials.gov) - Jan 13, 2015
P3, N=89, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Sep 2014 --> Sep 2015 Recruiting --> Active, not recruiting
- ||||||| Praluent (alirocumab) / Sanofi, Regeneron
Trial completion: ODYSSEY FH I: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (clinicaltrials.gov) - Jan 13, 2015
P3, N=471, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| evacetrapib (LY2484595) / Eli Lilly
Enrollment open, Combination therapy: A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia (clinicaltrials.gov) - Jan 9, 2015
P3, N=147, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | pradigastat (LCQ908) / Novartis
Enrollment closed: Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. (clinicaltrials.gov) - Jan 8, 2015
P3, N=38, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Enrollment closed, Enrollment change: Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression (clinicaltrials.gov) - Jan 8, 2015
P1, N=208, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=300 --> 208
- ||| Trial completion, Adherence: Statin Therapy to Improve Medication Adherence (clinicaltrials.gov) - Jan 8, 2015
P1, N=63, Completed, Sponsor: Duke University
Recruiting --> Active, not recruiting | N=300 --> 208 Active, not recruiting --> Completed
- | Brineura (cerliponase alfa) / BioMarin
Enrollment closed: A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease (clinicaltrials.gov) - Jan 6, 2015
P1/2, N=22, Active, not recruiting, Sponsor: BioMarin Pharmaceutical
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| hyzetimibe (HS-25) / Zhejiang Hisun
Trial completion: A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia (clinicaltrials.gov) - Jan 6, 2015
P2, N=376, Completed, Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Benecol (sitostanol ester) / J&J
Clinical: Serum Cholesterol Reduction Efficacy of Biscuit With Plant Stanol Ester (clinicaltrials.gov) - Jan 5, 2015
P=N/A, N=119, Completed, Sponsor: Raisio Group
- Clinical: WALDI: The Metabolic Effect of Walnuts in Healthy Subjects (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=180, Recruiting, Sponsor: Ludwig-Maximilians - University of Munich
- |||| bococizumab (RN316) / Pfizer
Enrollment open: Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects (clinicaltrials.gov) - Dec 30, 2014
P2, N=216, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Kynamro (mipomersen) / Kastle Therap
Enrollment closed, Trial primary completion date: MICA: Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis (clinicaltrials.gov) - Dec 30, 2014
P3, N=17, Active, not recruiting, Sponsor: Ludwig-Maximilians - University of Munich
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Apr 2015
- atorvastatin / Generic mfg., rosuvastatin / Generic mfg.
Enrollment change, Trial termination: The Therapeutic Effects of Statins and Berberine on the Hyperlipemia (clinicaltrials.gov) - Dec 29, 2014
P4, N=24, Terminated, Sponsor: Wenzhou Medical University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Apr 2015 N=60 --> 24 | Recruiting --> Terminated; Because of lack of participants and funds
- ||||||| Praluent (alirocumab) / Sanofi, Regeneron
Trial completion: Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term) (clinicaltrials.gov) - Dec 25, 2014
P3, N=2341, Completed, Sponsor: Sanofi
N=60 --> 24 | Recruiting --> Terminated; Because of lack of participants and funds Active, not recruiting --> Completed
- Enrollment change, Trial primary completion date: Effects of Amino Acids on Regional Lipid Metabolism (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=50, Recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Completed N=125 --> 50 | Trial primary completion date: Dec 2014 --> Jun 2015
- Clinical: Effect of Carnitine on Uremic Cardiomyopathy (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=60, Completed, Sponsor: Toujinkai Hospital